<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pediatric dosing guidance for the direct oral anticoagulant rivaroxaban</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pediatric dosing guidance for the direct oral anticoagulant rivaroxaban</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pediatric dosing guidance for the direct oral anticoagulant rivaroxaban</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Patient's weight</td> <td class="subtitle1_left">Rivaroxaban dose*</td> </tr> <tr> <td>2.6 to &lt;3 kg</td> <td>0.8 mg 3 times daily</td> </tr> <tr> <td>3 to &lt;4 kg</td> <td>0.9 mg 3 times daily</td> </tr> <tr> <td>4 to &lt;5 kg</td> <td>1.4 mg 3 times daily</td> </tr> <tr> <td>≥5 to &lt;7 kg</td> <td>1.6 mg 3 times daily</td> </tr> <tr> <td>≥7 to &lt;8 kg</td> <td>1.8 mg 3 times daily</td> </tr> <tr> <td>8 to &lt;9 kg</td> <td>2.4 mg 3 times daily</td> </tr> <tr> <td>9 to &lt;10 kg</td> <td>2.8 mg 3 times daily</td> </tr> <tr> <td>10 to &lt;12 kg</td> <td>3 mg 3 times daily</td> </tr> <tr> <td>12 to &lt;30 kg</td> <td>5 mg twice daily</td> </tr> <tr> <td>30 to &lt;50 kg</td> <td>15 mg once daily</td> </tr> <tr> <td>≥50 kg</td> <td>20 mg once <span class="nowrap_whitespace">daily<sup>¶</sup></span></td> </tr> </tbody></table></div><div class="graphic_lgnd">The dosing guidance in this table is for treatment of VTE in patients with normal kidney function. Patients should receive at least 5 days of parenteral anticoagulant therapy (eg, with LMWH or UFH) prior to transitioning to rivaroxaban. There are limited data on the use of rivaroxaban in pediatric patients with kidney impairment. Rivaroxaban should not be used in patients with severe kidney failure (ie, estimated glomerular filtration rate &lt;30 mL/minute). In addition, rivaroxaban should not be used in patients with severe liver disease (ie, alanine aminotransferase &gt;5 times the upper limit of normal, total bilirubin &gt;2 times the upper limit of normal with direct bilirubin &gt;20% of total, and/or coagulopathy due to liver disease).</div><div class="graphic_footnotes"><p>VTE: venous thrombosis and thromboembolism; LMWH: low molecular weight heparin; UFH: unfractionated heparin.</p>
<p>* Where available, rivaroxaban oral suspension should be used for patients weighing &lt;30 kg; rivaroxaban tablets or an oral suspension may be used for patients ≥30 kg. Tablets should not be split to achieve a lower dose.</p>
¶ This dose differs slightly from the recommended dose for treatment of VTE in adult patients, in whom a twice-daily dosing regimen is used for the first 21 days of therapy. In addition, adult patients can start rivaroxaban without initial parenteral therapy. If this approach is used in a pediatric patient weighing ≥50 kg (ie, if the patient is <strong>not</strong> treated with initial parenteral therapy), then the adult dosing regimen should be used. This consists of rivaroxaban 15 mg twice daily for 21 days, followed thereafter by 20 mg once daily.</div><div class="graphic_reference">References:
<ol>
<li>Janssen Pharmaceuticals. Product Monograph: Xarelto/rivaroxaban. 2021. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf</a> (Accessed on January 14, 2022).</li>
<li>Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020; 7:e18.</li>
</ol></div><div id="graphicVersion">Graphic 134264 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
